Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NexCAR19 in Relapsed/Refractory B-Cell Malignancies
NCT07502118Phase 3Recruiting
- Sponsor
- TÜSEB
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of MCARH109 in B cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), sponsored by TÜSEB. Started Sep 2025; status: recruiting.
02
Drugs
MCARH109
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07502118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502118.